Essential Thrombocythemia
📧 Sign up to get email alerts when something new happens for Essential Thrombocythemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-08-28Clinical Trial Update: Anti-TGF-beta Therapy in Patients With Myelofibrosis [Phase 1]
Phase 1 trial evaluating an anti-TGF-beta therapy in myelofibrosis was terminated; results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-07-29Clinical Trial Update: Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Exploratory multi-centre trial in essential thrombocythemia patients treated with XAGRID®. Completed with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-05-21Clinical Trial Update: 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial evaluating the combination of Triapine (3-AP) and fludarabine in various myeloproliferative disorders and advanced phases of c…
-
CLINICAL_TRIALS trial_result · 2014-02-25Clinical Trial Update: Imatinib Mesylate in Treating Patients With Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating Imatinib Mesylate in patients with myelofibrosis has completed. The study also addresses related myeloprol…
-
FDA label_change · 2014-02-07FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA page indicates Takeda submitted a supplemental NDA for AGRYLIN (anagrelide hydrochloride), signaling a labeling change under review.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-09-26Clinical Trial Update: Lenalidomide and Prednisone in Treating Patients With Myelofibrosis [Phase 2]
This Phase 2 trial evaluated lenalidomide in combination with prednisone for patients with myelofibrosis and related myeloproliferative neop…
-
CLINICAL_TRIALS trial_result · 2013-09-25Clinical Trial Update: Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia [Phase 3]
Phase 3 clinical trial exploring SPD422 for reducing platelets in Japanese adults at risk of essential thrombocythemia; study completed with…
-
CLINICAL_TRIALS trial_result · 2013-09-25Clinical Trial Update: French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Observational study in adults with essential thrombocythemia completed; results posted in 2013.
-
FDA approval · 2013-07-17FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda Pharmaceuticals America, Inc. The approva…
-
CLINICAL_TRIALS trial_result · 2013-06-17Clinical Trial Update: Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs
This clinical trial update reports on plasma vitamin and homocysteine levels and thrombosis in patients with Philadelphia-negative myeloprol…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia [Phase 2]
Phase 2 clinical trial update on tipifarnib for myelofibrosis and related myeloproliferative disorders, with the study having completed.
-
CLINICAL_TRIALS research · 2013-03-21Clinical Trial Update: Myeloproliferative Neoplasms and Bone Structure
This is a clinical trial update on myeloproliferative neoplasms and bone structure. The current status of the study is unknown.
-
FDA approval · 2013-02-13FDA Approved: ANAGRELIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for ANAGRELIDE from ANI Pharmaceuticals, Inc., authorizing a generic version of the drug. Anagrelide…
-
FDA approval · 2012-11-13FDA Approved: ANAGRELIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ANAGRELIDE (ANDA 076683) submitted by Chartwell RX, LLC. This appears to be a non-substantive ad…
-
CLINICAL_TRIALS trial_result · 2012-08-02Clinical Trial Update: Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
Open-label Phase 1/2 trial results for ruxolitinib (INCB018424) in patients with myelofibrosis, including those with post-polycythemia vera/…
-
CLINICAL_TRIALS trial_result · 2012-04-20Clinical Trial Update: A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis [Phase 1, Phase 2]
The Phase 1/2 study of oral SB1518 (pacritinib) in chronic idiopathic myelofibrosis has completed, with the trial listing other myeloprolife…
-
CLINICAL_TRIALS trial_result · 2012-02-24Clinical Trial Update: Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 study of ruxolitinib (INCB018424) in polycythemia vera and essential thrombocythemia was terminated, with results posted in 2012.
-
FDA label_change · 2012-01-26FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for DROXIA (hydroxyurea) from Waylis Therapeutics LLC, indicating a label change/expansion. The docu…
-
CLINICAL_TRIALS research · 2011-12-12Clinical Trial Update: A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia [Phase 2]
This is a Phase 2 clinical trial evaluating MK-0683 for efficacy in Polycythemia Vera and Essential Thrombocythemia; current status is unkno…
-
FDA approval · 2011-11-22FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2011-04-05Clinical Trial Update: A Safety Study of XL019 in Adults With Myelofibrosis [Phase 1]
This clinical trial update reports termination of a Phase 1 safety study of XL019 in adults with myelofibrosis and related myeloproliferativ…
-
FDA approval · 2011-01-31FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2010-10-06Clinical Trial Update: Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia [Phase 3]
This Phase 3 trial compared anagrelide to hydroxyurea in patients with essential thrombocythemia to assess efficacy and tolerability; the st…
-
FDA approval · 2010-08-31FDA Approved: ANAGRELIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for ANAGRELIDE by ANI Pharmaceuticals, Inc.
-
FDA approval · 2010-08-31FDA Approved: ANAGRELIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for ANAGRELIDE submitted by Chartwell RX, LLC under ANDA076683. This action completes the supple…